Abstract #LBA76: Hope Rugo presented interim OS results from the P3 TROPiCS-02 trial, which compared sacituzumabgovitecan (SG) (n=272) vs physician’s choice (n=271) in heavily pre-treated HR+/HER2- endocrine-resistant, unresectable locally advanced or metastatic breast cancer.
Results: SGdemonstrated significant improvement in OS (median: 14.4 vs 11.2 months for TPC),and significant improvement in objective response rate (21% vs 14%) and quality of life.
Thought leader reactions were moderately positive, with several welcoming any OS benefit in a population with limited treatment options. Comparisons to recent PFS data were positive:
However, some questioned the importance ofan overall survival benefit of only three months:
Several commentators hope and expect FDA approval for sacituzumab govitecan in this population:
One KOL would like to know the impact of this data on Trop-2 negative breast cancer patients and wonders why Trop-2 expression was not assessed.
This interim analysis of TROPiCS-2 OS data represents a positive step for this small population with limited treatment options. Some, however, consider the data only “incremental” or “modest”instead of game changing. Still, thought leaders expect FDA approval for sacituzumabgovite can in this population.
Synthesis by Opus Strategy, LLC
INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC)
NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)